bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Update

bioAffinity Technologies, Inc. (NASDAQ:BIAF) saw a large decline in short interest in January. As of January 31st, there was short interest totalling 396,800 shares, a decline of 7.2% from the January 15th total of 427,500 shares. Based on an average daily volume of 172,600 shares, the short-interest ratio is presently 2.3 days. Currently, 4.2% of the shares of the stock are sold short.

bioAffinity Technologies Trading Up 0.8 %

Shares of BIAF stock opened at $0.81 on Tuesday. The firm has a 50-day moving average price of $0.85 and a 200 day moving average price of $1.33. bioAffinity Technologies has a 12-month low of $0.57 and a 12-month high of $3.62. The company has a market capitalization of $12.63 million, a P/E ratio of -0.99 and a beta of 2.95. The company has a quick ratio of 1.01, a current ratio of 1.02 and a debt-to-equity ratio of 0.18.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC increased its stake in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) by 131.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,304 shares of the company’s stock after purchasing an additional 26,304 shares during the period. Sheaff Brock Investment Advisors LLC owned approximately 0.30% of bioAffinity Technologies worth $42,000 as of its most recent SEC filing. Institutional investors own 1.64% of the company’s stock.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.